Uncertainty surrounding projections of the long-term impact of ivermectin treatment on human onchocerciasis
about
The Onchocerciasis Vaccine for Africa--TOVA--InitiativeVaccination of Gerbils with Bm-103 and Bm-RAL-2 Concurrently or as a Fusion Protein Confers Consistent and Improved Protection against Brugia malayi InfectionResearch for new drugs for elimination of onchocerciasis in AfricaHuman Onchocerciasis: Modelling the Potential Long-term Consequences of a Vaccination ProgrammeFactors Associated with Ivermectin Non-Compliance and Its Potential Role in Sustaining Onchocerca volvulus Transmission in the West Region of CameroonDoes Increasing Treatment Frequency Address Suboptimal Responses to Ivermectin for the Control and Elimination of River Blindness?Elimination of African onchocerciasis: modeling the impact of increasing the frequency of ivermectin mass treatmentStability and change in the distribution of cytospecies of the Simulium damnosum complex (Diptera: Simuliidae) in southern Ghana from 1971 to 2011Onchocerciasis transmission in Ghana: biting and parous rates of host-seeking sibling species of the Simulium damnosum complex.The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial dataThe role of 'omics' in the quest to eliminate human filariasis.Modelling the impact of ivermectin on River Blindness and its burden of morbidity and mortality in African Savannah: EpiOncho projections.A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infectionReaching the london declaration on neglected tropical diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa.Onchocerciasis transmission in Ghana: persistence under different control strategies and the role of the simuliid vectors.Model-Based Geostatistical Mapping of the Prevalence of Onchocerca volvulus in West AfricaRequired duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis.Estimation of changes in the force of infection for intestinal and urogenital schistosomiasis in countries with schistosomiasis control initiative-assisted programmes.Modelling Anti-Ov16 IgG4 Antibody Prevalence as an Indicator for Evaluation and Decision Making in Onchocerciasis Elimination Programmes.Modelling the elimination of river blindness using long-term epidemiological and programmatic data from Mali and Senegal.Quantitative analyses and modelling to support achievement of the 2020 goals for nine neglected tropical diseases.Modelling Neglected Tropical Diseases diagnostics: the sensitivity of skin snips for Onchocerca volvulus in near elimination and surveillance settings.The genome of Onchocerca volvulus, agent of river blindness.Measuring and modelling the effects of systematic non-adherence to mass drug administration.Genome-wide analysis of ivermectin response by Onchocerca volvulus reveals that genetic drift and soft selective sweeps contribute to loss of drug sensitivity.Factors affecting onchocerciasis transmission: lessons for infection control.Macrofilaricidal Efficacy of Repeated Doses of Ivermectin for the Treatment of River Blindness.MODELING THE INFECTION DYNAMICS OF ONCHOCERCIASIS AND ITS TREATMENT
P2860
Q21562329-D9D8C46C-6018-43B9-B951-E1C3A584D132Q27303702-7A1AC737-44A3-4DC4-99D6-773D20F70915Q28066402-9D3F1E20-EB2B-4FD9-BBD1-CC195889FF1FQ28546650-9552F07F-03CE-49EB-BC63-DB290F11F811Q28553533-C6273534-93E6-46CC-AB5F-B62FF2E307B7Q28602538-2B2E17D7-E285-405A-B52D-C7A0DAB921CEQ28652963-CED274F7-2E28-4A95-850A-F63344753676Q28691621-8A77B60D-E610-4195-8CC2-0EF2F24ADC3BQ30602955-E23BB167-47B5-47B2-A256-BBF0B6522857Q30936469-B0F4C7DF-DC2D-4A26-B34B-1E7FE21F7900Q33584584-8CE518D0-DEDF-4A4F-ABEC-F3BEE5AC7287Q33681574-B2848E96-6279-4F73-94AA-4D97A516EA9DQ33812047-11E5CD62-1CF6-4213-BFE8-6DCAB4875D8AQ34202166-B8DCE209-28AF-48DB-968A-FAEC93699174Q35510635-6DA3C94C-8E8E-4B6A-A31E-1DB8976C0264Q35895175-522BCF2B-FFBD-4F36-9B90-196FAB746E0DQ36201881-C0530157-D68C-4496-AD4E-3BDCBC948458Q36204615-6A486F1A-DB18-4FC1-9553-2B4561F681D1Q36257358-A7181758-5AEF-4E08-8044-E01F506A78A8Q36303283-9017A3DF-BF44-48C0-BFB4-70678530A59DQ36361450-B0A6BA52-BA17-424F-991E-52C513017549Q37006791-5F4A8829-EC1D-4A77-8CAA-DCF733F84C14Q37643713-266F7580-A6BE-45BF-820A-20D0E6679407Q38916889-4D208DE0-B036-4354-8BE7-50C4F90747D8Q38977668-21F402CA-FC46-4A44-89C0-E8A5F2EB57A7Q40360250-C436B776-9C2F-45F6-89B4-5624B595E047Q41987224-7E849B6E-42FA-4AB0-8753-295E427935D3Q57189512-BFA07513-3C36-44E7-AAE9-6EA0B2E21385
P2860
Uncertainty surrounding projections of the long-term impact of ivermectin treatment on human onchocerciasis
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Uncertainty surrounding projec ...... atment on human onchocerciasis
@ast
Uncertainty surrounding projec ...... atment on human onchocerciasis
@en
Uncertainty surrounding projec ...... atment on human onchocerciasis
@nl
type
label
Uncertainty surrounding projec ...... atment on human onchocerciasis
@ast
Uncertainty surrounding projec ...... atment on human onchocerciasis
@en
Uncertainty surrounding projec ...... atment on human onchocerciasis
@nl
prefLabel
Uncertainty surrounding projec ...... atment on human onchocerciasis
@ast
Uncertainty surrounding projec ...... atment on human onchocerciasis
@en
Uncertainty surrounding projec ...... atment on human onchocerciasis
@nl
P2860
P50
P921
P3181
P1476
Uncertainty surrounding projec ...... atment on human onchocerciasis
@en
P2093
Mike Y Osei-Atweneboana
Roger K Prichard
P2860
P3181
P356
10.1371/JOURNAL.PNTD.0002169
P407
P577
2013-01-01T00:00:00Z